Drugs that contain Ruxolitinib Phosphate
1. List of Jakafi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
|
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(5 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(5 years from now) | |
|
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 22, 2028 |
| M (M) | Dec 19, 2025 |
| New Indication (I) | Sep 22, 2024 |
| Pediatric Exclusivity (PED) | Nov 24, 2026 |
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For treatment of polycythemia vera (pv) in patients who have had an inadequate respons...
Dosage: TABLET;ORAL
JAKAFI family patents
40
United States
15
European Union
13
Spain
10
Croatia
10
Denmark
10
Cyprus
10
Poland
10
Slovenia
10
RS
9
Portugal
9
Hungary
8
Hong Kong
7
New Zealand
6
EA
6
Israel
6
Korea, Republic of
6
Singapore
6
China
6
Taiwan
6
Lithuania
5
Japan
3
Ecuador
3
Malaysia
3
Costa Rica
3
Ukraine
3
Mexico
2
Australia
2
Canada
2
ME
2
South Africa
2
Cuba
2
Brazil
1
Colombia
1
Luxembourg
1
Dominican Republic
1
Tunisia
1
San Marino
1
Austria
1
Nicaragua
1
Morocco
1
Norway
1
Guatemala
1
Argentina
1
Georgia
1
Turkey
2. List of Opzelura drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US9974790 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US10639310 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
|
US9974790 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
|
US10639310 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
| US10610530 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(5 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(5 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(5 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US10610530 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
| US10758543 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
| US10869870 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
| US11219624 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
| US11571425 | INCYTE CORP | NA |
May, 2031
(7 years from now) | |
| US11590136 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
|
US10758543 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(8 years from now) | |
|
US11219624 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(8 years from now) | |
|
US10869870 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(8 years from now) | |
| US11590138 | INCYTE CORP | Topical treatment of vitiligo by a jak inhibitor |
Jun, 2040
(17 years from now) | |
| US11510923 | INCYTE CORP | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
Sep, 2040
(17 years from now) | |
| US11590137 | INCYTE CORP | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
Sep, 2040
(17 years from now) | |
| US11602536 | INCYTE CORP | Topical treatment of vitiligo by a JAK inhibitor |
May, 2041
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 21, 2024 |
| New Indication (I) | Jul 18, 2025 |
| Pediatric Exclusivity (PED) | Mar 21, 2025 |
Market Authorisation Date: 21 September, 2021
Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...
Dosage: CREAM;TOPICAL
OPZELURA family patents
51
United States
17
European Union
14
Spain
12
Japan
11
Croatia
11
Korea, Republic of
11
Denmark
11
Cyprus
11
Poland
11
Slovenia
11
RS
10
Hungary
9
Singapore
9
Portugal
9
Hong Kong
8
Australia
8
EA
8
New Zealand
8
China
7
Israel
7
Taiwan
6
Lithuania
5
Malaysia
4
Ecuador
4
Costa Rica
4
Ukraine
4
Mexico
3
Canada
3
ME
3
South Africa
3
Brazil
2
Colombia
2
Argentina
2
Cuba
2
San Marino
1
Luxembourg
1
Dominican Republic
1
Tunisia
1
Peru
1
Austria
1
Nicaragua
1
Chile
1
Morocco
1
Norway
1
Georgia
1
Guatemala
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic